Somatically derived ovarian yolk sac tumor in a postmenopausal woman: A case report of durable remission with personalized chemotherapy.

Vinita Popat, Adam Rucker, Joseph W Carlson, Aimee Keegan, Lorna Rodriguez-Rodriguez

Abstract readCase Reports

In one paragraph

Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vinita PopatDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.

Adam RuckerDepartment of Radiology, City of Hope National Medical Center, Duarte, CA, USA.

Joseph W CarlsonDivision of Anatomic Pathology, Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.

Aimee KeeganDepartment of Pharmacy, City of Hope National Medical Center, Duarte, CA, USA.

Lorna Rodriguez-RodriguezDivision of Gynecologic Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Somatically derived ovarian yolk sac tumors (SD-YSTs) in postmenopausal women are rare and typically present with advanced-stage disease, often carrying a poor prognosis. Case: We describe a 74-year-old woman with stage IIIB SD-YST who underwent complete surgical resection followed by cisplatin-etoposide chemotherapy, with bleomycin omitted due to frailty. Chemotherapy scheduling was modified in real time according to alpha-fetoprotein (AFP) kinetics, with treatment intervals shortened from 21 to 14 days after AFP levels rose between early cycles. Despite dose reductions due to thrombocytopenia, AFP levels normalized after cycle 3, and treatment was discontinued after cycle 4. Outcome: The patient has remained disease-free for over five years with ongoing surveillance. Conclusion: This case underscores the potential for long-term remission in SD-YST with platinum-based therapy, even when standard regimens require modification for older or frail patients. It highlights the value of biomarker-guided treatment adjustments to optimize chemotherapy timing in rare ovarian malignancies.

Indexed as

CA-125)Ovarian yolk sac tumorPersonalized treatment strategyPlatinum-based chemotherapySomatic differentiationTumor markers (AFP

Identifiers

PMID41439166

DOI10.1016/j.gore.2025.101989

PMCPMC12719060

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.